- Home
- PHGE vs INAB Comparison
PHGE vs INAB Comparison
Compare PHGE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- INAB
- Stock Information
- Founded
- PHGE 2015
- INAB 2016
- Country
- PHGE Israel
- INAB United States
- Employees
- PHGE N/A
- INAB N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- INAB Health Care
- Exchange
- PHGE Nasdaq
- INAB Nasdaq
- Market Cap
- PHGE 26.5M
- INAB 23.5M
- IPO Year
- PHGE N/A
- INAB 2021
- Fundamental
- Price
- PHGE $0.75
- INAB $0.36
- Analyst Decision
- PHGE Strong Buy
- INAB Strong Buy
- Analyst Count
- PHGE 2
- INAB 3
- Target Price
- PHGE $22.50
- INAB $7.75
- AVG Volume (30 Days)
- PHGE 151.9K
- INAB 2.7M
- Earning Date
- PHGE 11-14-2024
- INAB 11-12-2024
- Dividend Yield
- PHGE N/A
- INAB N/A
- EPS Growth
- PHGE N/A
- INAB N/A
- EPS
- PHGE N/A
- INAB N/A
- Revenue
- PHGE N/A
- INAB N/A
- Revenue This Year
- PHGE N/A
- INAB N/A
- Revenue Next Year
- PHGE N/A
- INAB N/A
- P/E Ratio
- PHGE N/A
- INAB N/A
- Revenue Growth
- PHGE N/A
- INAB N/A
- 52 Week Low
- PHGE $0.62
- INAB $0.22
- 52 Week High
- PHGE $8.55
- INAB $2.48
- Technical
- Relative Strength Index (RSI)
- PHGE 36.37
- INAB 50.42
- Support Level
- PHGE $0.67
- INAB $0.31
- Resistance Level
- PHGE $0.81
- INAB $0.37
- Average True Range (ATR)
- PHGE 0.09
- INAB 0.04
- MACD
- PHGE 0.00
- INAB 0.01
- Stochastic Oscillator
- PHGE 44.00
- INAB 38.51
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.